- Home
- STRS vs PBYI Comparison
STRS vs PBYI Comparison
Compare STRS & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRS
- PBYI
- Stock Information
- Founded
- STRS 1992
- PBYI 2010
- Country
- STRS United States
- PBYI United States
- Employees
- STRS N/A
- PBYI N/A
- Industry
- STRS Homebuilding
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- STRS Real Estate
- PBYI Health Care
- Exchange
- STRS Nasdaq
- PBYI Nasdaq
- Market Cap
- STRS 155.7M
- PBYI 164.3M
- IPO Year
- STRS N/A
- PBYI N/A
- Fundamental
- Price
- STRS $20.38
- PBYI $3.54
- Analyst Decision
- STRS
- PBYI Strong Buy
- Analyst Count
- STRS 0
- PBYI 1
- Target Price
- STRS N/A
- PBYI $7.00
- AVG Volume (30 Days)
- STRS 17.7K
- PBYI 306.9K
- Earning Date
- STRS 08-12-2025
- PBYI 07-31-2025
- Dividend Yield
- STRS N/A
- PBYI N/A
- EPS Growth
- STRS N/A
- PBYI 143.51
- EPS
- STRS N/A
- PBYI 0.77
- Revenue
- STRS $32,719,000.00
- PBYI $232,709,000.00
- Revenue This Year
- STRS N/A
- PBYI N/A
- Revenue Next Year
- STRS N/A
- PBYI N/A
- P/E Ratio
- STRS N/A
- PBYI $4.64
- Revenue Growth
- STRS N/A
- PBYI 2.68
- 52 Week Low
- STRS $15.10
- PBYI $2.23
- 52 Week High
- STRS $30.66
- PBYI $4.13
- Technical
- Relative Strength Index (RSI)
- STRS 59.33
- PBYI 58.27
- Support Level
- STRS $18.50
- PBYI $3.26
- Resistance Level
- STRS $19.61
- PBYI $3.65
- Average True Range (ATR)
- STRS 1.11
- PBYI 0.14
- MACD
- STRS 0.12
- PBYI 0.01
- Stochastic Oscillator
- STRS 100.00
- PBYI 82.83
About STRS Stratus Properties Inc.
Stratus Properties Inc is a diversified real estate company operating in the United States. It is engaged in the acquisition, entitlement, development, management, operation and sale of commercial, multi- and single-family residential real estate properties, located in the Austin Texas area and other select markets in Texas. It operates its business through two segments namely, Real Estate Operations and Leasing Operations. Real Estate Operations segment encompasses activities associated with entitlement, development, and sale of real estate. Leasing Operations segment involves leasing of commercial space at retail and mixed-use properties and residences in multi-family properties that company developed. Majority of revenue is from Real Estate Operations.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.